Obsessive–compulsive disorder (OCD) is a debilitating neuropsychiatric condition characterized by intrusive obsessions and compulsions, and when resistant to conventional treatments, it poses a profound clinical challenge. Until now, the genetic factors that specifically contribute to treatment resistance in OCD, as compared to other mental disorders such as depression, bipolar disorder, or schizophrenia, have remained poorly understood. The present study aimed to address this gap by investigating the influence of genetic variants—particularly single nucleotide polymorphisms (SNPs)—within the HTR2A gene, which encodes a critical serotonin receptor implicated in cognitive and emotional regulation.

The study retrospectively analyzed a cohort of 210 individuals diagnosed with various TRMDs. This cohort included 72 patients with major depressive disorder, 62 with bipolar disorder, 37 with schizophrenia, 30 with OCD, and 9 with other psychiatric disorders. Extensive genetic screening was performed on blood samples via next-generation sequencing technology, focusing on three HTR2A SNPs: rs6314, rs7997012, and rs6311. These polymorphisms were selected due to their documented involvement in serotonergic signaling pathways and previous associations with psychiatric conditions.

Statistical analysis employing chi-square tests and both single- and multiple-SNP approaches revealed intriguing patterns of association. Notably, the rs7997012 SNP emerged as a robust genetic marker distinctly linked to TR-OCD. Individuals homozygous for the A allele (A|A genotype) at rs7997012 exhibited a dramatically higher likelihood—nearly seven times greater—of belonging to the TR-OCD group compared to those with the G|G genotype, a finding underscored by a highly significant p-value (< 0.001).

Moreover, when comparing the A|A genotype against a combined group of G|G and A|G genotypes, this elevated risk remained statistically significant, reinforcing the potential specificity of rs7997012 in identifying OCD patients with treatment resistance. These findings indicate that the rs7997012 polymorphism may serve not merely as a susceptibility marker but more importantly as a genetic discriminator separating TR-OCD from other mental health disorders exhibiting treatment resistance.

Beyond isolated SNP effects, the study delved into haplotype analyses of the combined genotypes from rs6314, rs7997012, and rs6311. The global haplotype association was significant, with the combined genetic variants collectively influencing OCD treatment resistance. Specifically, the G-G-C haplotype was associated with a reduced risk of TR-OCD relative to the reference G-G-T haplotype, suggesting complex gene-gene interactions within serotonergic pathways that modulate the clinical phenotype of OCD.

These insights are particularly consequential given the centrality of serotonin neurotransmission in both the pathophysiology of OCD and the mechanisms of action of many psychotropic medications. The HTR2A gene encodes the 5-HT2A receptor subtype, a critical receptor involved in serotonin-mediated signal transduction in the brain regions implicated in OCD, such as the orbitofrontal cortex, basal ganglia, and anterior cingulate cortex. Variations affecting the expression or function of this receptor could influence neuronal circuitry and cognitive control processes underlying obsessive–compulsive behaviors, thereby contributing to differential treatment outcomes.

The implications of this study extend beyond academic curiosity, hinting at the dawn of personalized medicine approaches for OCD. By identifying genetic polymorphisms that reliably distinguish treatment-resistant patients, clinicians could tailor pharmacological interventions, opting for agents targeting specific serotonin receptor subtypes or developing novel therapeutics aimed at correcting the dysfunctional signaling pathways uncovered by genetic profiling.

While the findings are preliminary and require replication in larger, ethnically diverse populations, they nonetheless elevate the HTR2A rs7997012 polymorphism as a prime candidate for future research on OCD’s biological substrates. It stimulates the broader scientific discourse on how different mental disorders with overlapping clinical features yet diverse molecular etiologies might be more accurately categorized and managed.

In practical terms, the implementation of genotyping for the rs7997012 SNP alongside other serotonergic markers could eventually become integrated into psychiatric diagnostic protocols, improving prognostic accuracy. Patients identified as carriers of risk alleles might be prioritized for more aggressive or alternative therapeutic strategies earlier in the course of the illness, aiming to circumvent the protracted suffering commonly associated with treatment-resistant OCD.

Furthermore, this research underscores the necessity of multidisciplinary approaches, combining psychiatry, genetics, and neurobiology, to tackle the complexity of psychiatric illnesses. It also highlights the transformative potential of next-generation sequencing technologies in unveiling subtle yet impactful genetic variations that modulate disease phenotypes.

In conclusion, this seminal investigation sheds light on the crucial role of the HTR2A gene’s polymorphisms, notably rs7997012, in delineating treatment-resistant obsessive–compulsive disorder from other resistant psychiatric conditions. By deepening our understanding of the serotonergic system’s genetic architecture, it opens new avenues for developing precision psychiatry models, heralding a future where mental illness treatment is as personalized and effective as interventions in other fields of medicine.

Strong evidence now positions the HTR2A rs7997012 A|A genotype as a significant biomarker for TR-OCD, offering hope that such genetic insights will translate into improved patient outcomes. As researchers continue to unravel OCD’s genetic underpinnings, targeted therapies built upon these discoveries promise to alleviate the burden of this often intractable disorder, making previously elusive recovery a tangible goal.

Subject of Research: The role of 5-hydroxytryptamine receptor 2A (HTR2A) gene polymorphisms in distinguishing treatment-resistant obsessive-compulsive disorder (TR-OCD) from other treatment-resistant mental disorders (TRMDs).

Article Title: The role of 5-hydroxytryptamine receptor 2A (HTR2A) gene polymorphisms in treatment-resistant obsessive–compulsive disorder: a comparative study with other treatment-resistant mental disorders.

Article References:
Del Casale, A., Gentile, G., Arena, J.F. et al. The role of 5-hydroxytryptamine receptor 2A (HTR2A) gene polymorphisms in treatment-resistant obsessive–compulsive disorder: a comparative study with other treatment-resistant mental disorders. BMC Psychiatry 25, 938 (2025). https://doi.org/10.1186/s12888-025-07301-5

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07301-5

OCD, characterized by intrusive thoughts and repetitive behaviors, is widely recognized as a multifactorial disorder, with both genetic predispositions and environmental stimuli playing critical roles. Previous studies have implicated the serotonin biosynthesis pathway, particularly the TPH2 gene, which codes for the rate-limiting enzyme in serotonin production within the brain. Serotonin’s influence on mood and behavior is well documented, but this investigation sheds light on epigenetic modifications—specifically DNA methylation—that alter TPH2 expression, potentially modulating serotonin synthesis in ways that exacerbate OCD symptoms.

To dissect this gene-environment interrelationship, the research team recruited 58 individuals diagnosed with OCD alongside 89 age- and gender-matched healthy control subjects. Employing the highly sensitive MassARRAY system, methylation levels at 12 CpG sites—regions where methyl groups attach to DNA to regulate gene expression—within the TPH2 promoter were quantified. Such granularity enabled the researchers to detect subtle but statistically significant differences in methylation patterns correlated with both OCD presence and symptom severity.

One of the remarkable findings was the identification of CpG site 6 methylation as a robust biomarker linked with OCD diagnosis, maintaining significance even after rigorous Bonferroni correction for multiple comparisons. This indicates that hyper- or hypomethylation at this locus may materially influence TPH2 gene activity, thereby modifying serotonin availability in neural circuits implicated in OCD. This insight invites further exploration into specific epigenetic targets for pharmacological intervention aimed at normalizing serotonin levels.

Beyond molecular data, the study innovatively integrated evaluations of the family environment using validated psychometric tools: the Family Assessment Device (FAD) and the Egna Minnen Barndoms Uppfostran (EMBU) questionnaire. The former assesses dimensions of family functioning such as communication, roles, and emotional involvement, while the latter explores retrospective perceptions of parenting styles, including dimensions like punishment and parental preference. These assessments allowed the researchers to correlate familial context with epigenetic markers and clinical measures of OCD severity.

Intriguingly, methylation levels at CpG sites 2 and 1/3/8 demonstrated inverse relationships with the ‘general functioning’ and ‘roles’ subscales of the FAD respectively, reflecting that poorer family dynamics may be associated with decreased methylation at these sites. Conversely, CpG site 7 methylation positively correlated with ‘affective involvement’, suggesting that nuanced aspects of emotional engagement within the family environment might influence epigenetic modulation differentially across the TPH2 promoter.

Moreover, the presence or absence of specific parenting styles detected via EMBU corresponded with significant differences in methylation at several CpG sites (2, 4, 5, 9, and 10). These observations imply that early life environmental inputs, perhaps related to parental control or warmth, could leave lasting epigenetic imprints that alter gene regulation patterns relevant to OCD risk. Such evidence supports the notion of epigenetic plasticity shaped by childhood experiences, contributing to the disorder’s heterogeneity.

Symptom severity, measured objectively by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), was also linked to epigenetic and familial variables. Elevated methylation at CpG sites 6, 9, and 12 was associated with higher Y-BOCS scores, reinforcing the functional impact of these epigenetic marks on clinical expression. Importantly, several dimensions of family functioning (problem-solving, communication, affective responsiveness, and general functioning) alongside paternal punitive behavior and maternal preference bore significant correlations with OCD severity, emphasizing the influential role of family milieu.

These findings collectively suggest a gene–environment interaction model wherein adverse family environments could mediate OCD vulnerability through epigenetic regulation of the TPH2 gene and subsequent disruption of serotonergic pathways. Such a model provides a compelling framework integrating biological, psychological, and social domains, encouraging multifaceted treatment strategies that address both neurobiological and environmental contributors to OCD.

The implications for future research are profound. Understanding how environmental stressors translate to epigenetic modifications opens avenues for preventative interventions in at-risk populations, potentially via psychosocial support or epigenetic therapeutics. Furthermore, these results advocate for incorporating familial assessments into clinical practice to better tailor interventions that acknowledge the patient’s contextual background alongside their molecular profile.

As the field of psychiatric epigenetics evolves, this study exemplifies the power of combining cutting-edge molecular biology with comprehensive clinical and psychosocial evaluations. The nuanced correlations between TPH2 methylation and family dynamics highlight that individual susceptibility to OCD may hinge not solely on fixed genetic inheritance but also on modifiable environmental exposures and their biological echoes.

In conclusion, this research pioneers a holistic perspective on OCD pathogenesis by elucidating how DNA methylation of the TPH2 gene and family functioning collaboratively influence symptom severity. By bridging molecular genetics and family psychology, it charts a promising path toward personalized medicine in psychiatry, where therapeutic decisions could be informed by the interplay between one’s epigenome and psychosocial context. This integrative approach holds transformative potential for improving outcomes for millions afflicted by OCD worldwide.

Subject of Research: The study investigates the combined effects of TPH2 gene DNA methylation and family environment factors, including parenting styles and family functioning, on the etiology and symptom severity of obsessive-compulsive disorder (OCD).

Article Title: Influence of TPH2 DNA methylation and family functioning, parenting styles on OCD severity

Article References:
Wang, L., Chen, Y., Hu, S. et al. Influence of TPH2 DNA methylation and family functioning, parenting styles on OCD severity. BMC Psychiatry 25, 882 (2025). https://doi.org/10.1186/s12888-025-07217-0

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07217-0